174 related articles for article (PubMed ID: 7545844)
1. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].
Wirth MP; Pilarsky C
Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
3. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
Stamey TA
Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
5. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
6. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
7. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
8. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
9. [Value of determining prostate specific antigen in follow-up of prostatic cancer].
Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C
Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556
[TBL] [Abstract][Full Text] [Related]
10. [Can the tumor stage of prostate carcinoma be determined with the aid of prostate-specific antigen?].
Semjonow A; Hertle L
Urologe A; 1995 Jul; 34(4):290-6. PubMed ID: 7545843
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
12. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
[TBL] [Abstract][Full Text] [Related]
13. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
14. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
15. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
Simmons MN; Stephenson AJ; Klein EA
Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
[TBL] [Abstract][Full Text] [Related]
16. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
17. [Prostatic specific antigen for detection and monitoring of prostatic cancer].
Gofrit O; Pode D; Gez E; Pfau A; Roizman I; Lifshitz Y; Barak V
Harefuah; 1992 Mar; 122(6):345-8, 408. PubMed ID: 1374729
[TBL] [Abstract][Full Text] [Related]
18. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
19. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
[TBL] [Abstract][Full Text] [Related]
20. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
